Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13899773 | 0.88 | PAOX (0.42) | PAOXALDH1A1MAPTSIGMAR1MEN1 | |
| SCHEMBL6600771 | 0.85 | SMN1; SMN2 (0.45) | ALDH1A1MAPTSIGMAR1SMN1; SMN2 | |
| SCHEMBL13880146 | 0.83 | SMN1; SMN2 (0.48) | ALDH1A1MAPTSIGMAR1SMN1; SMN2 | |
| SCHEMBL6446184 | 0.80 | GLA (0.40) | PAOXALDH1A1SMN1; SMN2MEN1KMT2A | |
| SCHEMBL6652891 | 0.80 | ALDH1A1 (0.54) | ALDH1A1MAPTSIGMAR1SMN1; SMN2MEN1 | |
| SCHEMBL16708776 | 0.79 | CARM1 (0.44) | SIGMAR1MEN1KMT2AHTR1A | |
| SCHEMBL15065306 | 0.77 | SIGMAR1 (0.46) | PAOXSIGMAR1 | |
| SCHEMBL19212956 | 0.75 | PIM1 (0.39) | PAOXALDH1A1MAPTSIGMAR1MC4R | |
| SCHEMBL134397 | 0.75 | PIM1 (0.39) | PAOXALDH1A1MAPTSIGMAR1MC4R | |
| SCHEMBL14142584 | 0.75 | PIM1 (0.39) | PAOXALDH1A1MAPTSIGMAR1MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504399-B2 | Piperazine enamines as antiviral agents | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070287712-A1 | Piperazine Enamines as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287712-A1 | Piperazine Enamines as Antiviral Agents | INMT, ITPA, IDO1 | PAOX 3670/4885ALDH1A1 1893/4885MAPT 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.